This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

TechAtlas Group Releases Type 1 Diabetes Competitive Landscape Analysis

BOSTON, Sept. 6, 2013 /PRNewswire/ -- TechAtlas Group has announced the release of the latest Type 1 Diabetes (T1DM) competitive landscape map. This particular landscape highlights 71 international companies with over 140 drugs and devices currently on the market and in development.

(Logo: http://photos.prnewswire.com/prnh/20130517/NE16011LOGO )

Topics include:

  • Save the cells: immune therapies for T1DM
  • Beta-cell regeneration strategies
  • Pancreatic replacement via cell-based therapy
  • Therapeutic considerations: childhood, adolescence, adulthood & older adults
  • Managing hypoglycemia: new pens and bi-hormonal systems
  • Competitive positioning in the insulin market
  • Non-insulin add-on therapies for tighter glycemic control
  • Strategic implications of artificial pancreas development

TechAtlas' analysts have evaluated each clinical asset according to the parameters that dictate their commercial competitiveness, including clinical benefit/risk, cost, patient preference, and reimbursement dynamics. For example, competition in this field is driving the creation of longer-lasting (7+ days use), slimmer CGMs to increase patient acceptance. However, the need for frequent finger-stick blood glucose calibrations presents a critical obstacle to CGM use, which will only be resolved by significant technical advances that lower the mean absolute relative difference (MARD) of the CGMs. Meanwhile, new stable glucagon formulations are laying the foundation for better hypoglycemic control by facilitating simpler rescue pen systems and, more importantly, bi-hormonal delivery pumps that will contribute to the "holy grail" – a fully independent artificial pancreas system.

The TechAtlas map graphically presents every T1DM-related technology, old and new, in its proper context to clearly show the relationship of competing and complementary products for specific unmet needs and ideal treatment paradigms like T1DM prevention and development of the artificial pancreas. This map was built on extensive primary research, including interviews with companies, investors, key opinion leaders in the diabetes community, academic researchers, technical experts, consumers of technologies, and other stakeholders in the field, as well as an exhaustive review of public and proprietary resources.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,279.74 +13.75 0.08%
S&P 500 2,010.40 -0.96 -0.05%
NASDAQ 4,579.7890 -13.6380 -0.30%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs